| Miriam Pearl Finkel, MD | |
|
6990 Lindsay Dr, Mentor, OH 44060-4981 | |
| (440) 290-9616 | |
| (667) 218-3669 |
| Full Name | Miriam Pearl Finkel |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 9 Years |
| Location | 6990 Lindsay Dr, Mentor, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043606189 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | MD467487 (Pennsylvania) | Secondary |
| 207N00000X | Dermatology | 35.143035 (Ohio) | Primary |
| Entity Name | Radiant Dermatology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518621663 PECOS PAC ID: 0143610618 Enrollment ID: O20211124001730 |
News Archive
There is no high quality evidence that antioxidant supplements help to increase a woman's chances of having a baby, according to the results of a new systematic review. The review, published in The Cochrane Library, found women were no more likely to conceive when taking oral antioxidants and that there was limited information about potential harms.
HemCon Medical Technologies, Inc., announced today that the U.S. Court of Appeals for the Federal Circuit granted HemCon's motion to stay the injunction and final judgment (including the damages award) obtained against it in a patent infringement case brought by Marine Polymer Technologies, Inc.
A new study from the UK shows that the presence of inequality favors a heavier impact and that this showed dynamic changes as policies changed and newer virus variants emerged.
Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE® (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE® 3 to 5 months after transplant.
› Verified 8 days ago
| Entity Name | Compass Dermatopathology Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922312248 PECOS PAC ID: 7113112558 Enrollment ID: O20220926003687 |
News Archive
There is no high quality evidence that antioxidant supplements help to increase a woman's chances of having a baby, according to the results of a new systematic review. The review, published in The Cochrane Library, found women were no more likely to conceive when taking oral antioxidants and that there was limited information about potential harms.
HemCon Medical Technologies, Inc., announced today that the U.S. Court of Appeals for the Federal Circuit granted HemCon's motion to stay the injunction and final judgment (including the damages award) obtained against it in a patent infringement case brought by Marine Polymer Technologies, Inc.
A new study from the UK shows that the presence of inequality favors a heavier impact and that this showed dynamic changes as policies changed and newer virus variants emerged.
Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE® (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE® 3 to 5 months after transplant.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Miriam Pearl Finkel, MD 6990 Lindsay Dr Ste 1and5, Mentor, OH 44060-4981 Ph: (440) 290-9616 | Miriam Pearl Finkel, MD 6990 Lindsay Dr, Mentor, OH 44060-4981 Ph: (440) 290-9616 |
News Archive
There is no high quality evidence that antioxidant supplements help to increase a woman's chances of having a baby, according to the results of a new systematic review. The review, published in The Cochrane Library, found women were no more likely to conceive when taking oral antioxidants and that there was limited information about potential harms.
HemCon Medical Technologies, Inc., announced today that the U.S. Court of Appeals for the Federal Circuit granted HemCon's motion to stay the injunction and final judgment (including the damages award) obtained against it in a patent infringement case brought by Marine Polymer Technologies, Inc.
A new study from the UK shows that the presence of inequality favors a heavier impact and that this showed dynamic changes as policies changed and newer virus variants emerged.
Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE® (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE® 3 to 5 months after transplant.
› Verified 8 days ago
Dr. William Vincent Krug, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 9485 Mentor Ave Ste 102, Mentor, OH 44060 Phone: 440-266-5500 | |
Dr. Anthony J Castrovinci, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 7915 Munson Rd, Mentor, OH 44060 Phone: 440-951-2304 Fax: 440-951-2304 | |
Alexandra Rae Harris, C.N.P. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9485 Mentor Ave Ste 210, Mentor, OH 44060 Phone: 440-255-5571 Fax: 440-205-5744 |